About Human Genome Sciences (NASDAQ:HGSI)
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Human Genome Sciences (NASDAQ:HGSI) Frequently Asked Questions
What is Human Genome Sciences' stock symbol?
Human Genome Sciences trades on the NASDAQ under the ticker symbol "HGSI."
Has Human Genome Sciences been receiving favorable news coverage?
News articles about HGSI stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Human Genome Sciences earned a daily sentiment score of 0.15 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Human Genome Sciences?
Shares of HGSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Human Genome Sciences?
Human Genome Sciences' mailing address is 14200 Shady Grove Rd, ROCKVILLE, MD 20850-7464, United States. The biopharmaceutical company can be reached via phone at +1-301-3098504.
MarketBeat Community Rating for Human Genome Sciences (HGSI)MarketBeat's community ratings are surveys of what our community members think about Human Genome Sciences and other stocks. Vote "Outperform" if you believe HGSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGSI will underperform the S&P 500 over the long term. You may vote once every thirty days.